BTBD1

Across TCGA pan-cancer cohorts, BTBD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BTBD1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BTBD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BTBD1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where BTBD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.740	0.924	.003	47	view →
PDAC	DFS	Median	II,III,IV	0.243	0.549	<.001	36	view →
HNSC	DFS	Quartile	II,III,IV	0.969	0.675	.010	18	view →
CCRCC	OS	Median	IV	0.451	1.000	.016	12	view →
LSCC	DFS	Median	All	0.493	0.832	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BTBD1–LUAD (OS)

Open the LUAD breakdown →